Journal article
A Proteomic Approach for the Discovery of Early Detection Markers of Hepatocellular Carcinoma
Disease markers, v 17(3)
2001
PMID: 11790885
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Individuals chronically infected with hepatitis B or C virus (HBV, HCV) are at high risk for the development of hepatocellular carcinoma (HCC), with disease progression occurring relentlessly over many years. The diagnosis of HCC usually occurs at late stages in the disease when there are few effective treatment options and the prognosis for patients with HCC is very poor. The long latency period, together with clearly identified at risk populations, provide opportunities for earlier detection that will allow more timely and effective treatment of this devastating cancer. We are using a proteomic approach to test the hypothesis that changes in the amount of certain serum polypeptides, or changes in their post-translational modifications, can be used to predict the onset of HCC. Advances in the standardization of two dimensional gel electrophoresis (2DE) coupled with computerized image analysis now permit the reproducible resolution of thousands of polypeptides per run. Serum polypeptides from individuals at different stages in the disease continuum are being resolved by 2DE to identify those that change with disease progression. Polypeptides found by this method can be further characterized by mass spectrometry. In addition, the potential for changes in the glycan structure of certain polypeptides to serve as a marker for disease progression can be explored. The proteomic approach is expected to liberate us from the need to “cherry pick” or guess the best biomarkers and let the data tell us which are the best indicators of disease. Information may also be gleaned about the pathobiology of the disease process.
Metrics
Details
- Title
- A Proteomic Approach for the Discovery of Early Detection Markers of Hepatocellular Carcinoma
- Creators
- Laura F Steel - Department of Biochemistry and Molecular Pharmacology, Jefferson Center for Biomedical Research, Thomas Jefferson University, Doylestown, PA 18901, USATaj S Mattu - Department of Biochemistry and Molecular Pharmacology, Jefferson Center for Biomedical Research, Thomas Jefferson University, Doylestown, PA 18901, USAAnand Mehta - Department of Biochemistry and Molecular Pharmacology, Jefferson Center for Biomedical Research, Thomas Jefferson University, Doylestown, PA 18901, USAHolger Hebestreit - Oxford Glycobiology Institute, University of Oxford, Oxford OX1 3QU, UKRaymond Dwek - Oxford Glycobiology Institute, University of Oxford, Oxford OX1 3QU, UKAlison A Evans - Fox Chase Cancer Center, Philadelphia, PA 19101, USAW. Thomas London - Fox Chase Cancer Center, Philadelphia, PA 19101, USATimothy Block - Department of Biochemistry and Molecular Pharmacology, Jefferson Center for Biomedical Research, Thomas Jefferson University, Doylestown, PA 18901, USA
- Publication Details
- Disease markers, v 17(3)
- Publisher
- Wiley
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology; Epidemiology and Biostatistics
- Web of Science ID
- WOS:000172808400012
- Scopus ID
- 2-s2.0-0035668456
- Other Identifier
- 991014878575704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Biotechnology & Applied Microbiology
- Genetics & Heredity
- Medicine, Research & Experimental
- Pathology